Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study

Abstract

A phase II study (PRIMMO) of patients with pretreated persistent/recurrent/metastatic cervical or endometrial cancer is presented. Patients received an immunomodulatory five-drug cocktail (IDC) consisting of low-dose cyclophosphamide, aspirin, lansoprazole, vitamin D, and curcumin starting 2 weeks before radioimmunotherapy. Pembrolizumab was administered three-weekly from day 15 onwards; one of the tumor lesions was irradiated (8Gyx3) on days 15, 17, and 19. The primary endpoint was the objective response rate per immune-related response criteria (irORR) at week 26 (a lower bound of the 90% confidence interval [CI] of > 10% was considered efficacious). The prespecified 43 patients (cervical, n = 18; endometrial, n = 25) were enrolled. The irORR was 11.1% (90% CI 2.0–31.0) in cervical cancer and 12.0% (90% CI 3.4–28.2) in endometrial cancer. Median duration of response was not reached in both cohorts. Median interval-censored progression-free survival was 4.1 weeks (95% CI 4.1–25.7) in cervical cancer and 3.6 weeks (95% CI 3.6–15.4) in endometrial cancer; median overall survival was 39.6 weeks (95% CI 15.0–67.0) and 37.4 weeks (95% CI 19.0–50.3), respectively. Grade ≥ 3 treatment-related adverse events were reported in 10 (55.6%) cervical cancer patients and 9 (36.0%) endometrial cancer patients. Health-related quality of life was generally stable over time. Responders had a significantly higher proportion of peripheral T cells when compared to nonresponders (p = 0.013). In conclusion, PRIMMO did not meet its primary objective in both cohorts; pembrolizumab, radiotherapy, and an IDC had modest but durable antitumor activity with acceptable but not negligible toxicity.Trial registration ClinicalTrials.gov (identifier NCT03192059) and EudraCT Registry (number 2016-001569-97).

Abscopal Effect after Stereotactic Body Radiotherapy with Nivolumab for Lung Metastasis of Head and Neck Cancer: A Case Report

“…The authors acknowledge the insufficient sample size and the favourable results of nivolumab alone in the metastatic HNSCC control group. Similar negative results have been reported for other carcinomas [ 16 , 17 ]. In these trials that aimed to induce the AE in patients with metastasis, SBRT was often delivered at relatively low doses, such as 24–30 Gy in three fractions.…”

Top Ten Lessons Learned from Trials in Oligometastatic Cancers

“…A pooled analysis of the PEMBRO-RT and MDACC trials assessed metastatic NSCLC patients receiving pembrolizumab with or without radiotherapy found that patients undergoing radiation had a higher abscopal response rate (41.7% vs. 19.7%) [ 41 ]. However, other phase II clinical trials that evaluated the combination of SABR and immunotherapy have failed to demonstrate the abscopal effect in a variety of histologies [ 42 ] including renal cell carcinoma [ 43 ], head and neck [ 44 ], NSCLC [ 45 ], cervical/endometrial [ 46 ] and colorectal cancer [ 47 ]. This includes the ongoing CHEERS trial, a multicenter phase II trial randomizing locally advanced or metastatic patients to receive SABR and anti-PD-(L)1 immunotherapy or immunotherapy alone.…”

The Preventive Role of the Vitamin D Endocrine System in Cervical Cancer

“…In 2010, a Japanese case-control study including 405 patients with incidental cervical neoplasias found that cervical cancer risk was reduced by increasing vitamin D intake [26], suggesting that vitamin D plays a protective role for cervical cancer. To date, no clinical trials have been conducted that have demonstrated the expected beneficial effects of vitamin D 3 , 25OHD 3 or calcitriol per se on women with invasive cervical cancer, but they have been developed in combination with other antineoplastic drugs, including a phase II study (NCT03192059) that enrolled cervical or endometrial cancer patients, who received a cocktail of low-dose of cyclophosphamide, aspirin, lansoprazole, vitamin D, and curcumin starting 2 weeks before radioimmunotherapy; the antitumor activity was modest but durable, and the toxicity was acceptable but not negligible [81]. A limited number of clinical trials have studied the effect of long-term vitamin D supplementation on precancerous lesions of the cervix.…”